Grey M, Boland E A, Tamborlane W V
Yale School of Nursing, Yale University, New Haven, Connecticut (Dr Grey and Ms Boland)
Yale School of Medicine, Yale University, New Haven, Connecticut (Dr Tamborlane)
Diabetes Educ. 1999 Nov-Dec;25(6):934-41. doi: 10.1177/014572179902500611.
This study examined the metabolic and quality-of-life effects of using lispro insulin in teenagers.
Teenagers on multiple daily injections who had not reached metabolic treatment goals were offered the opportunity to use lispro insulin as part of a larger ongoing study of intensive management in youth. Of the 51 who were eligible, 35 used lispro and were followed for 12 months; the remaining 16 had reached treatment goals, were not offered lispro, and comprised the control group.
After 12 months, the teens who received lispro insulin achieved equivalent levels of metabolic control to those achieved by teens in the control group, without differences in total daily dose, insulin regimen, or adverse events. Those who received lispro found coping with diabetes less difficult than those who continued on regular insulin, and they reported less negative impact of diabetes on quality of life and fewer worries about diabetes. Both groups were equally satisfied with their diabetes treatment.
Lispro insulin is a safe alternative for youth on intensive regimens, may assist youth in coping with diabetes, and may improve their quality of life.
